Viridian Therapeutics, Inc.VRDNNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank38
5Y CAGR-59.2%
Studio
Year-over-Year Change

Direct costs attributable to producing goods sold

5Y CAGR
-59.2%/yr
Long-term compound
Percentile
P38
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
TTM$320000.00-
2024$0.00-
2023$0.00-
2022$0.00-
2021$0.00-100.0%
2020$28.30M-
2019$0.00-100.0%
2018$30.42M+55.0%
2017$19.62M+670.1%
2016$2.55M-